Multicenter, Non-randomised, Open-label, Single Agent Phase II Study to Determine the Clinical Benefit of Trastuzumab Emtansine (T-DM1) in HER2-positive Metastatic Breast Cancer Patients With Brain Metastasis
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2018
Price : $35 *
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- Acronyms KIARA
- 28 Nov 2018 Planned End Date changed from 1 Jul 2020 to 27 Aug 2018.
- 28 Nov 2018 Planned primary completion date changed from 1 Jul 2020 to 27 Aug 2018.
- 28 Nov 2018 Planned initiation date changed from 1 Jul 2017 to 23 Feb 2018.